Cargando…

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells

Resistance to CDK4/6 inhibitors (CDKis) is emerging as a clinical challenge. Identification of the factors contributing to CDKi resistance, with mechanistic insight, is of pivotal significance. Recent studies linked aberrant FGFR signaling to CDKi resistance. However, detailed mechanisms are less cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Qiong, Ma, Zhikun, Shi, Yujie, Parris, Amanda B., Kong, Lingfei, Yang, Xiaohe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616148/ https://www.ncbi.nlm.nih.gov/pubmed/34831231 http://dx.doi.org/10.3390/cells10113008

Ejemplares similares

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
por: Mouron, Silvana, et al.
Publicado: (2021)

Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice
por: Parris, Amanda B., et al.
Publicado: (2017)

FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
por: Zhao, Qingxia, et al.
Publicado: (2017)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway
por: Guo, Zhiying, et al.
Publicado: (2017)

GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells
por: Booth, Laurence, et al.
Publicado: (2022)

FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype
por: Levine, Kevin M., et al.
Publicado: (2019)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021)

FGFR1 is an adverse outcome indicator for luminal A breast cancers
por: Shi, Yu-Jie, et al.
Publicado: (2015)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells
por: Lanceta, Lilibeth, et al.
Publicado: (2020)

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
por: Haines, Eric, et al.
Publicado: (2018)

Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling
por: Zhang, Xi, et al.
Publicado: (2013)

Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells
por: Lee, Harry, et al.
Publicado: (2018)

TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer
por: Seksenyan, Akop, et al.
Publicado: (2015)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR
por: Li, Lei, et al.
Publicado: (2019)

CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities
por: Terry, Stéphane, et al.
Publicado: (2015)

Bisphenol AF promotes estrogen receptor-positive breast cancer cell proliferation through amphiregulin-mediated crosstalk with receptor tyrosine kinase signaling
por: Zhao, Qingxia, et al.
Publicado: (2019)

In Utero Exposure to Bisphenol a Promotes Mammary Tumor Risk in MMTV-Erbb2 Transgenic Mice Through the Induction of ER-erbB2 Crosstalk
por: Ma, Zhikun, et al.
Publicado: (2020)

Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
por: Chen, Lin, et al.
Publicado: (2019)

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer
por: Theelen, Willemijn SME, et al.
Publicado: (2016)

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2017)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells
por: Lin, Sheng-Li, et al.
Publicado: (2009)

ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function
por: Bado, Igor, et al.
Publicado: (2018)

Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities
por: Terry, Stéphane, et al.
Publicado: (2019)

FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
por: Mieczkowski, Kamil, et al.
Publicado: (2022)

FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT via two independent mechanisms
por: Szymczyk, Jakub, et al.
Publicado: (2022)

Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways
por: Lee, Yoon Jin, et al.
Publicado: (2020)

Daam1 Overexpression Promotes Gastric Cancer Progression and Regulates ERK and AKT Signaling Pathways
por: Zhang, Yue, et al.
Publicado: (2021)

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
por: Turczyk, Lukasz, et al.
Publicado: (2017)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

MiR‐3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway
por: Kong, Shiqi, et al.
Publicado: (2020)

PRMT5/FGFR3/AKT Signaling Axis Facilitates Lung Cancer Cell Metastasis
por: Zheng, Yonghua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8vn8bmt482f0gvk9vk2g4g3qs1